82VS — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Cantai Therapeuticscantaitx.cominNov 2023 · $3M
Cantai develops rationally designed bispecific antibodies that combine clinically validated mechanisms to treat patients with autoimmune disease.
BiotechHealthtechPhiladelpia, US
Errik Anderson(Executive Officer, Director)inRoss Leimberg(Executive Officer, Director)in
BoardJoshua Brandt(Director)Geeta Vemuri(Executive Officer, Director)in
Co-investorsAgent Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.